ArticleFrontiers in pharmacology2022

WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6.

Jing Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.